In a small open dose-finding study the i.v. dose of ICI 35 868 required to induce anaesthesia in healthy adults was 2 mg kg-1 . Comparison of this dose with Althesin 0.05 ml kg-1 for i.v. induction, both injected over 30 s suggests that they have similar effects on heart rate, arterial pressure and breathing. The mean times to loss of eyelash reflex were 57 ± SD 10.1 s (ICI 35 868) and 46 ± SD 3.9 s (Althesin). The new drug was associated with pain and discomfort on injection in seven of 10 patients, but with less involuntary movement than occurred with Althesin.
ICI 35 868 (2 : 6-diisopropylphenol) is a new i.v. anaesthetic drug which has shown promising results in animal studies (Glen, 1980) and in preliminary clinical trials in Belgium (Kay and Roily, 1977) . In 1979 the Committee on Safety of Medicines gave permission for pilot studies of the drug in the U.K. The authors received permission to conduct a doubleblind comparison of ICI 35 868 with Althesin as induction agents, on condition that not more than 20 patients received the new drug. The suggested dose of ICI 35 868 1 mg kg-1 i.v. (Kay and Roily, 1977) failed to induce anaesthesia and consequently half of the allocated administrations were deployed in a short dose-finding study from which it was concluded that the appropriate dose was 2 mg kg-1 . We report here the results of the open dose-finding study and of the double-blind comparison in 20 patients.
PATIENTS AND METHODS
A total of 30 patients in good general health, aged 17-50 yr and within 10% of the expected body weight gave written permission for the study. None was receiving concurrent drug therapy (including oral contraceptives) and none had a previous history of atopy or allergy. Since the present formulation of ICI 35 868 includes Cremophor EL 16% (w/v) as a solubilizing agent we ensured that no patient had received a previous Cremophor-containing anaesthetic, or indeed any anaesthetic in the past 10 years if The anaesthetic procedure was standardized. Premedication was with diazepam 0.15 mg kg-1 given orally 60-90 min before induction. The induction agent was given over 30 s into a vein in the back of the hand via a 21-gauge indwelling (butterfly type) needle. At the end of the injection 5 ml of isotonic saline was injected rapidly to clear the deadspace of the needle. If, after 2 min from the start of injection, anaesthesia, judged by abolition of the eyelash reflex, had not been induced (this occurred only with the smaller doses of ICI 35 868) Althesin was injected until the agreed end-point was reached. Two minutes after the start of injection (or immediately following induction of anaesthesia in the patients who required the second injection) a facemask was applied and anaesthesia was continued with appropriate concentrations of halothane in 70% nitrous oxide in oxygen.
Drug doses
In the initial dose-finding study in 10 patients, ICI 35 868 was given in the following doses: 1 mg kg" 1 (three patients), 1.5 mg kg" 1 (four), 2 mg kg" 1 (two) and 2.5 mg kg-1 (one). For the comparative study the dose of ICI 35 868 was 2 mg kg-1 and of Althesin 0.05 ml kg" 1 ; at this dose the volume of the Althesin injection would have been half that of the ICI 35 868 preparation and so the Althesin was diluted in an equal volume of isotonic saline to facilitate the double-blind technique. For each patient studied there were two anaesthetist observers and a third anaesthetist who prepared the injections.
Measurement and observations in the double-blind study
Induction time: from the start of injection to the abolition of the eyelash reflex.
Symptoms: pain or discomfort on injection, and other clinical observations such as involuntary movements.
E.c.g.: recorded from three conventionally placed chest leads.
Heart rate: counted automatically from the output of an ear-lobe plethysmograph.
Breathing pattern: respiratory frequency and tidal spirogram were obtained using an inductance plethysmograph (Hanning, Smith and Ledingham, 1978) . The heart rate, respiratory frequency and spirogram were recorded on a multi-channel Linzeis chart recorder.
Arterial pressure measured with an oscillotonometer was recorded immediately before induction, at 50, 110 and 180 s following the start of injection and at approximately 5-min intervals thereafter.
One and two minutes from the start of injection the response to the application of a sterile towel clip to the medial aspect of the thigh was noted.
Blood sampling. On the day before and on the day after surgery, venous blood was sampled for biochemical and haematological estimations.
Before induction of anaesthesia a 14-gauge cannula was inserted to a vein in the antecubital fossa of the arm opposite to that which was used for drug injection. From some patients who were known, after operation, to have received ICI 35 868, voided urine was collected for a 24-h period in dry sterile bottles. The blood and urine were analysed for the content of the induction drugs or metabolites. The data from this aspect of the study, part of a larger collection, will be presented in a later publication.
Postoperative evaluation. The patient's opinion of both induction and recovery from anaesthesia was sought immediately after wakening and at 24 h after operation. The vein used for the induction injection was examined for signs of tissue damage immediately after injection and after 24 h; each patient was questioned by telephone about the condition of the hand after 3 weeks.
Biochemical and haematological assessment. Biochemical estimations included serum electrolytes, glucose, bilirubin, protein and enzyme indications of liver cell integrity. The haematological survey consisted of haemoglobin, differential white cell count and platelet numbers.
RESULTS

Dose-finding study
On the basis of 10 injections of ICI 35 868 with doses ranging from 1 mg kg" 1 to 2.5 mg kg" 1 we concluded that the dose required for induction of anaesthesia in the manner described was approximately 2 mg kg-1 (table I) . 
Double-blind study
The mean induction times were 46 ± SD 3.9 s for Althesin and 57 ± SD 10.1 s for ICI 35 868. Applying Student's t test this small difference was statistically significant (P<0.05).
The cardiovascular responses to the two drugs were remarkably similar. The average reduction in mean arterial pressure in both groups was approximately 6% at 50 and 110 s after injection compared with the pre-injection baseline (table II) . At the same Seven of 10 patients receiving ICI 35 868 complained of some form of discomfort in the hand and arm during injection whereas there were no such complaints following Althesin (table III) . However, there were no abnormal sequelae in the vein used for injection in any patient.
Involuntary movement occurred in four patients receiving Althesin and one receiving ICI 35 868. The response to application of a towel dip to the leg was similar for the two drugs (table III) . All of the patients appeared to be satisfied with their experience of the induction of anaesthesia and there were no obvious untoward events such as dreaming or hallucinations.
There were no obvious abnormalities in the haematological data or in the serum electrolyte concentrations before and 24 h after anaesthesia. Neither were there any obvious abnormalities in liver function tests. However, we noted a small increase in the serum bilirubin concentration in seven of the patients who received ICI 35 868. In all but one instance the values remained within the normal range for the hospital laboratory.
DISCUSSION
These preliminary studies indicate that when used in the manner described in this study a suitable induction dose of ICI 35 868 is approximately 2mgkg-1 . However, the method of dose-finding employed by us was crude as a consequence of the limited number of injections which we were permitted to administer. In spite of our uncertainty about the dose, it seemed appropriate to compare our initial experience of the new agent with Althesin as an example of a better known i.v. anaesthetic, the pharmacological profile and formulation of which was not dissimilar to that of the new compound.
The results suggest that, as with Althesin, ICI 35 868 provides a reliable induction of anaesthesia with no unpleasant after-effects. Although no patient found the experience unpleasant in retrospect, the complaints of pain in the hand and arm during injection of ICI 35 868 must be regarded as an important disadvantage of the compound. It may be that changes in the formulation can lead to a lessening of this problem. The cardiovascular stability associated with ICI 35 868 was impressive. The respiratory depression produced by the new compound was slightly more marked than that with Althesin, but we would not regard this as a serious disadvantage in clinical practice.
The pharmacokinetic profile of ICI 35 868 in animals (Adams, Glen and Hoyle, 1980) indicates a compound that might be expected to provide rapid recovery from anaesthesia and to be particularly suitable for administration to outpatients. Similarly, a compound with these characteristics would be worthy of evaluation as a continuous i.v. anaesthetic although it is not possible to predict from the present studies that it would be a satisfactory anaesthetic if used as the sole agent EXPERIENCE PRELIMINAIRE AVEC ICI 35 868 UTILISE COMME AGENT DTNDUCTION PAR VOIE INTRAVEINEUSE: COMPARAISON AVEC L'ALTHESLNE RESUME Au court d'une petite etude libre pour trouver les doses appropriies, la dose d'ICI 35 868 requise pour provoquer l'anesthesie sur des adultes en bonne santi a ete de 2 mg kg" 1 . La comparaison de cette dose avec l'althesine administr£e a raison de 0,05 ml kg~l pour l'induction par voie intraveineuse, toutes deux injecttes en moins de 30 s, laisse penser qu'elles ont des effets similaires sur la frequence cardiaque, la pression arterielle et la respiration. Les temps moyens pour arriver a la perte du riflexe de cillement ont tti de 57 s±erreur type 10,1 s (pour ICI 35 868) et de 46 s ± erreur type de 3,9 s (pour Palthfaine). Le nouvel agent a et6 associi a des douleurs et des malaises au moment de 1'injection sur 7 patients sur 10, mais a moins de mouvements involontaires tels que ceux qui se sont produits avec l'althisine. 
SUMARIO
Durante un pequeno estudio para averiguar la dosis necesaria para inducir anestesia en adultos sanos, mediante ICI 35 868, se concluy6 que esta era de 2 ing kg-1 . La comparaci6n de estas dosis con 0.05 ml kg" 1 de altesina para producir inducci6n intravenosa, ambas dosis inyectadas a lo largo de 30 segundos, sugirid que estas cantidades ejercian efectos similares sobre el ritmo cardiaco, la presi6n arterial y la respiracidn. El promedio de tiempo para perdCT el reflejo del parpado fue de 57±desviaci6n tipica de 10,1 (para el ICI 35 868) y de 46±desviaci6n tfpica de 3,9 (para la altesina). La inyeccidn de la neuva droga vino asociada con dolor y molestias en 7 de los 10 pacientes, pero con un menor movimiento involuntario que el acaeddo con la altesina.
